Is Flexion Therapeutics (FLXN) a Smart Long-term Buy? All news about FLEXION THERAPEUTICS, INC. 11/19: FLEXION THERAPEUTICS INC: Results of Operations and Financial Condition (form 8.. AQ. Learn more. Recent Stock Performance. Our data indicates that Flexion Therapeutics, Inc. has a market capitalization of US$615m, and total annual CEO compensation was reported as US$3.8m for the year to December 2019. Flexion Therapeutics (NASDAQ:FLXN) 's stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a report issued on Monday, AnalystRatings.com reports. Get prepared with the key expectations. View FLXN's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. News. FLXN - Flexion Therapeutics Inc Reuters News. Flexion resumed enrollment in Phase 1 dose-escalation trial for FX201; FX301 on track to enter clinic in 2021; BURLINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for … Flexion’s strategy is to build a robust pipeline of locally administered therapies to address musculoskeletal conditions, with an initial focus on osteoarthritis (OA). Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGM - NasdaqGM Real Time Price. Learn more. Flexion (FLXN) Soars: Stock Adds 6.6% in Session, Planning For A Rebound In Flexion Therapeutics, Why Flexion Therapeutics Is Tumbling 10% Today, Flexion under pressure after pricing equity offering, Flexion Therapeutics Announces Pricing of Public Offering of Common Stock, Flexion Therapeutics Announces Proposed Public Offering of Common Stock, How Flexion Therapeutics (FLXN) Stock Stands Out in a Strong Industry, Flexion Therapeutics to Present at the RBC Capital Markets 2020 Virtual Global Healthcare Conference, Flexion Therapeutics Inc (FLXN) Q1 2020 Earnings Call Transcript, Edited Transcript of FLXN earnings conference call or presentation 7-May-20 8:30pm GMT, Receive Analysts' Upgrades and Downgrades Daily. Get the latest Flexion Therapeutics, Inc. (FLXN) stock news and headlines to help you in your trading and investment decisions. Stable Share Price: FLXN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week. Flexion shares halted on news of FDA approval for knee pain injection Oct. 6, 2017 at 3:10 p.m. (AP) _ Flexion Therapeutics Inc. (FLXN) on Wednesday reported a loss of $24.6 million in its third quarter. Flexion Therapeutics hasn't issued any revenue guidance for the time being. Flexion Therapeutics Inc. annual stock financials by MarketWatch. Latest Share Price and Events. Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights finance.yahoo.com - August 5 at 6:35 PM: Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020 finance.yahoo.com - July 30 at 5:55 PM: Flexion Therapeutics (FLXN) Is Up 9.84% in One Week: What You Should Know Flexion Therapeutics Inc. (NASDAQ: FLXN) is -37.15% lower on its value in year-to-date trading and has touched a low of $5.01 and a high of $22.98 in the current 52-week trading range. The company hosted a conference call on October FLXN - Flexion Therapeutics Inc Share News. Year-to-date, Flexion Therapeutics Inc (NASDAQ:FLXN) stock lost 42.1% and on October 30th it … Fundamental company data provided by Morningstar and Zacks Investment Research. To see all exchange delays and terms of use please see disclaimer. (AP) _ Flexion Therapeutics Inc. (FLXN) on Wednesday reported a loss of $24.6 million in its third quarter. Learn about financial terms, types of investments, trading strategies and more. * Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $23.7 million in third quarter 2020 BURLINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended September 30, 2020.“Throughout the third quarter, we saw … Export data to Excel for your own analysis. Latest Share Price and Events. Flexion’s strategy is to build a robust pipeline of locally administered therapies to address musculoskeletal conditions, with an initial focus on osteoarthritis (OA). But FLXN stock started tumbling at the beginning of the year.Source: Shutterstock And despite positive news about its flagship drug, Zilretta, it's struggling to reclaim its gains.There's a reason for that. Year-to-date, Flexion Therapeutics Inc (NASDAQ: FLXN ) stock lost 42.1% …